Fig. 3
HCC PDOs with different CD44 levels exhibited different sensitivitities to sorafenib. a Representative bright-field images of HCC PDOs (patient 1 and patient 4) that were exposed to sorafenib at the indicated concentration for 6 days are shown. DMSO-treated PDOs were used as controls. Scale bar, 200 μm. b Sorafenib reduced the viability of 4 HCC PDOs in a dose-dependent manner. DMSO-treated PDOs were used as controls, and the mean of two independent experiments performed with three duplicates is shown. c The differential IC50 values (μM) of 4 HCC PDOs are shown as the mean ± SD. d HCC PDOs were exposed to sorafenib for 6 days, and cell viability was recorded daily. e Kaplan-Meier overall survival curves for patients with low or high CD44 expression from TCGA are shown. (* p < 0.05, P < 0.05 is considered statistically significant)